单细胞分辨率下解码良性前列腺增生：异质性、炎症及雄激素驱动发病机制之外的探索
Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.
摘要(中文译文)
良性前列腺增生（BPH）是一种高度流行的年龄相关性疾病，传统上通过雄激素驱动通路进行管理。然而，常规激素治疗在相当一部分患者中疗效有限，这促使人们探索替代性致病机制。单细胞RNA测序（scRNA-seq）的出现为绘制前列腺内细胞异质性和微环境动态提供了必要的分辨率。本综述综合了scRNA-seq应用于BPH研究的最新进展，强调了从同质的、以激素为中心的观点向将BPH视为由多方面细胞-免疫相互作用驱动的复杂异质性过程的转变。我们详细阐述了scRNA-seq如何识别增生移行区内不同的细胞亚群，包括新型基底上皮亚型和活化成纤维细胞群体，这些细胞直接参与结节形成和疾病进展。此外，我们审视了慢性炎症的核心作用，该过程由免疫细胞浸润和衰老相关分泌表型（SASP）介导，维持着促增殖微环境。该技术还阐明了治疗抵抗的潜在机制，并识别了雄激素轴之外的潜在生物标志物和新型治疗靶点，如CXCL13/CD4T细胞轴和颗粒酶K通路。展望未来，将scRNA-seq与空间多组学整合旨在构建BPH的全面时空图谱，促进分子分型及精准的微环境靶向疗法的开发。总之，scRNA-seq正在重新定义BPH的病理生理格局，为旨在实现真正疾病修饰的创新性非雄激素治疗策略开辟了道路。
Abstract
Benign prostatic hyperplasia (BPH) represents a highly prevalent age-related disorder, traditionally managed through androgen-driven pathways. However, the limited efficacy of conventional hormonal therapies in a substantial subset of patients necessitates the investigation of alternative pathogenic mechanisms. The emergence of single-cell RNA sequencing (scRNA-seq) has provided the necessary resolution to map cellular heterogeneity and microenvironmental dynamics within the prostate. This review synthesizes recent advancements in applying scRNA-seq to BPH research, highlighting a transition from a homogeneous, hormone-centric view toward recognizing BPH as a complex, heterogeneous process driven by multifaceted cell-immune interactions. We detail how scRNA-seq has identified distinct cellular subsets within the hyperplastic transition zone, including novel basal epithelial subtypes and activated fibroblast populations that contribute directly to nodule formation and disease progression. Furthermore, we examine the central role of chronic inflammation, mediated by immune cell infiltration and senescence-associated secretory phenotypes (SASP), in perpetuating a proliferative microenvironment. The technology also clarifies mechanisms underlying treatment resistance and identifies potential biomarkers and novel therapeutic targets beyond the androgen axis, such as the CXCL13/CD4T cell axis and granzyme K pathways. Looking forward, integrating scRNA-seq with spatial multi-omics aims to construct a comprehensive spatiotemporal atlas of BPH, facilitating molecular subtyping and the development of precision, microenvironment-targeted therapies. In conclusion, scRNA-seq is redefining the pathophysiological landscape of BPH, offering a path toward innovative, non-androgenic therapeutic strategies aimed at achieving true disease modification.
如何引用
AMA
Yihao Liao, Siyuan Jiang, Haohan Wang, Sihai Zhou, Honggang Yuan, Xuanxuan Zou, et al. Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.. Frontiers in immunology. 2026; doi:10.3389/fimmu.2026.1881717.
APA
Yihao Liao, Siyuan Jiang, Haohan Wang, Sihai Zhou, Honggang Yuan, Xuanxuan Zou, et al (2026). Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.. Frontiers in immunology. https://doi.org/10.3389/fimmu.2026.1881717
GB/T 7714
Yihao Liao, Siyuan Jiang, Haohan Wang, Sihai Zhou, Honggang Yuan, Xuanxuan Zou, et al. Decoding benign prostatic hyperplasia at single-cell resolution: heterogeneity, inflammation, and beyond androgen-driven pathogenesis.[J]. Frontiers in immunology, 2026 doi:10.3389/fimmu.2026.1881717.
在 PubMed增强版 阅读全文
翻译全文 · AI 文献问答 · PDF 原文下载 · 引用导出